Biocryst Pharmaceuticals INC 8-K filings

BioCryst Pharmaceuticals initiates legal action to protect its ORLADEYO patents from generic competition.

BioCryst Pharmaceuticals' Chief Financial Officer, Anthony Doyle, has announced his resignation, effective April 9, 2025.

BioCryst Pharmaceuticals announces positive Q4 and full year 2024 financial results, driven by strong ORLADEYO sales, and raises its 2025 revenue guidance.

BioCryst Pharmaceuticals will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, with presentation slides available on their investor relations website starting January 13, 2025.

BioCryst reports a 34% year-over-year increase in ORLADEYO net revenue for 2024 and anticipates approaching quarterly profitability in the second half of 2025.

BioCryst Pharmaceuticals is increasing the wholesale acquisition cost of ORLADEYO in the United States effective January 8, 2025.

BioCryst Pharmaceuticals announced a strong third quarter with significant revenue growth for ORLADEYO, leading to increased full-year revenue guidance and advancements in their pipeline.

BioCryst Pharmaceuticals has begun a Phase 1 clinical trial for BCX17725, a novel kallikrein 5 inhibitor, aimed at treating Netherton syndrome.

BioCryst Pharmaceuticals has been awarded a contract of up to $69 million by the U.S. Department of Health and Human Services for the supply of RAPIVAB, an influenza treatment, to the Strategic National Stockpile.

BioCryst Pharmaceuticals announced a 34% year-over-year increase in ORLADEYO net revenue for Q2 2024, leading to an increased full-year revenue guidance and a GAAP operating profit.

BioCryst Pharmaceuticals' stockholders approved an amendment to the company's Stock Incentive Plan, increasing the number of shares available for issuance by 7,000,000.

BioCryst Pharmaceuticals announced a successful first quarter of 2024, highlighted by a 30 percent year-over-year increase in ORLADEYO revenue and an upward revision of its full-year revenue guidance.

BioCryst Pharmaceuticals announced positive financial results for Q4 and full year 2023, driven by strong growth of ORLADEYO, and anticipates operating profit in 2024.

BioCryst Pharmaceuticals updated its by-laws to align with Delaware law and clarify procedures for stockholder meetings and director nominations.